Well said. And remember there’s a total of 5 clinical trials...

Well said. And remember there’s a total of 5 clinical trials running concurrently with a six trial yet to come into the mix.

There’s no capital required in the foreseeable future and any strategic raise will occur at much higher prices IMO.

The company has just demonstrated they believe in the programs by not taking US capital at a time that did not benefit shareholders. Why? Because the board have more skin in the game than anyone and they’ve got the best insight into the status of the trials.

If ever we needed a vote of confidence then that is it. They’ve got my vote, I’ve been buying and will continue to do so where I can.